Takeda took a $2.5 billion Japanese yen legal charge after a pay-for-delay antitrust verdict in Boston. A federal jury found Takeda liable in a class-action case tied to Amitiza (constipation drug) and ordered damages of at least $885 million, with potential automatic trebling under antitrust law. Takeda said it will pursue post-trial motions and appeal, and emphasized the verdict did not change FY2026 guidance. Still, the earnings impact underscores how intellectual-property and market-entry disputes can become material balance-sheet events even after a product exits company sales. The case was notable as the first time a jury found a drugmaker liable in a pay-for-delay matter, increasing scrutiny of settlement structures across branded and generic markets.